As far as we have come we need to start planning for the eventuality of Medicare for all, and an expectation that in the not to distant future disease treatments will contribute to the reduction in healthcare costs. Medical treatment of disease will likely enter a transformative stage when better diagnostics through use of artificial intelligence, and targeted pesonal genetic modifications in the form of Gene theraphy impact long term disease outcomes.

Synergies among disciplines are attracting big tech companies such as Google, Amazon, Facebook, Apple to the life sciences industry. Incorporation of artificial intelligence and cloud-based solutions for drug discovery and clinical trial workflow will help improve the overall production efficiency. Moreover pathology and research laboratories have adopted health analytics solutions to track test utilization and to tackle reimbursement issues.
Additionally, a National Healthcare notion will give way to Medicare as a major Entity. This may drive down drug prices.

Dan one question will arise shortly regarding the future flood of treatments arriving from today's CRISP collabdortive work, and the degree that it can be monetized, and reduced to practice versus the traditional manufactured pharmaceuticals. WHEN Gene theraphy or one of it's analogues mainstream's the acceptance practice of it as an individualized treatment custom for your genotype and particular circumstance, we will see a truly disruptive change in the method of pricing healthcare solutions. Not to mention the potential for eliminating costly surgeries, long term medicinal treatments for cancer, diabetes, and many other conditions.

CMS

Federal law has made it illegal to provide pro-bono care to Medicaid or Medicare patients.

Any thoughts?

Medicare likely to evolve into more of a Part C/Advantage dominant program.
Stricter coverage criteria more similar to commercial plans today.